Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avastin approved for lung cancer
Avastin will be used to specifically target non-small cell lung cancer, the most common type of lung cancer. The approval is based on a phase III study that
Avastin will be used to specifically target non-small cell lung cancer, the most common type of lung cancer. The approval is based on a phase III study that
In a preliminary assessment of the application, the EMEA reviewers indicated that additional clinical data would be needed prior to potential approval. The company has said that based
“Based on the results we have generated to-date, MBP8298 appears to have the potential to fundamentally alter the course of this devastating disease,” said Kevin Giese, president and
Gene Logic's drug repositioning program seeks to find alternative development paths for drug candidates with good safety records. The program offers pharmaceutical partners a new approach to help
Oral TLF is currently in phase II clinical development for RCC. Talactoferrin Alfa is a unique recombinant form of human lactoferrin, known as an immunomodulatory protein. “Metastatic RCC
Clinical trials to date have demonstrated that treatment with Galvus results in sustained reductions in blood sugar levels, leading to improved glucose control. The most common side effects
The submission is based on safety and efficacy studies that evaluated bifeprunox for the treatment of schizophrenia. Patients were evaluated with acute exacerbations for six weeks, and stable
COPD, or chronic obstructive pulmonary disease, is a complex lung disease that results in a progressive decline in lung function that is ultimately debilitating and life-threatening. Results of
BPH is a condition in which the prostate gland becomes enlarged, placing increased pressure around the urethra resulting in difficult and painful urinary flow. Current drug and surgical
Under the terms of this agreement, Ambrilia grants Merck the exclusive worldwide rights to its lead compound, PPL-100. In return Ambrilia receives an upfront licensing fee of $17